| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB-ADAZ | 13 |
| 1 | BEVACIZUMAB | 9 |
| 2 | ALLOPURINOL | 8 |
| 3 | BISOPROLOL FUMARATE | 7 |
| 4 | CARBOPLATIN | 7 |
| 5 | CELECOXIB | 7 |
| 6 | DULOXETINE | 7 |
| 7 | DULOXETINE HYDROCHLORIDE | 7 |
| 8 | GABAPENTIN | 7 |
| 9 | MESALAMINE | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TILDRAKIZUMAB-ASMN | 1 | 0.0004 |
| 1 | MITOMYCIN | 1 | 0.0003 |
| 2 | MESALAMINE | 7 | 0.0002 |
| 3 | ADALIMUMAB-ADAZ | 13 | 0.0002 |
| 4 | VALPROIC ACID | 7 | 0.0002 |
| 5 | TORSEMIDE | 7 | 0.0002 |
| 6 | ADALIMUMAB-FKJP | 6 | 0.0001 |
| 7 | PANITUMUMAB | 2 | 0.0001 |
| 8 | SUCRALFATE | 3 | 0.0001 |
| 9 | ADALIMUMAB-AATY | 6 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Aluminum Complex [EPC] | 3 | 0.0001 |
| 1 | Aminosalicylate [EPC] | 7 | 0.0001 |
| 2 | Influenza A M2 Protein Inhibitor [EPC] | 1 | 0.0001 |
| 3 | Epidermal Growth Factor Receptor Antagonist [EPC] | 3 | 0.0001 |
| 4 | Integrin Receptor Antagonist [EPC] | 5 | 0.0001 |
| 5 | Platinum-based Drug [EPC] | 14 | 0.0001 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 9 | 0.0000 |
| 7 | Xanthine Oxidase Inhibitor [EPC] | 8 | 0.0000 |
| 8 | Interleukin-23 Antagonist [EPC] | 4 | 0.0000 |
| 9 | Microtubule Inhibitor [EPC] | 6 | 0.0000 |